The Prolieve® Transurethral ThermoDilatation™ Therapy (TUTD™) offers a unique “Thermo+Dilatation” treatment for symptoms of enlarged prostate, also known as benign prostatic hyperplasia (BPH). Prolieve® is FDA approved and is the least invasive BPH treatment on the market.
With the balloon compressing the prostate, Prolieve® is a dual modality therapy simultaneously treating the gland with Focused Heat and Dilatation. With the 5-Year patient follow up approved and accepted by FDA in 2018, Prolieve® has been proven fast, safe and effective.
94% of the patients do not require a post treatment catheter and the associated risks including retrograde ejaculation and erectile dysfunction are extremely low. Majority of patients experience significant and immediate relief, and the treatment results are also sustainable.
The treatment is a 45-minute, in-office, outpatient procedure which is performed and well-tolerated under local anesthesia. There is no need to go to the hospital and patients can return to their normal daily life right after the treatment.
Our Prolieve TUTD Advantages Over Other Minimally-Invasive BPH Therapies
| Proven Immediate Symptom Relief & Long-Term Safety, Efficacy & Durability | Yes |
| Appealing to Patients: Fewer Post-Treatment Catheterization | Yes |
| No Foreign Bodies or Clips left within the Urinary Tract | Yes |
| No Puncture of Prostatic Urethra to minimize Pain & Hemorrhage | Yes |
| No/Minimal Sexual Side Effects (E.D. & Retrograde Ejaculation) | Yes |
| Rectal Temperature Monitoring for Added Safety to the rectum & neurovascular bundles | Yes |
| Our Experienced Technicians assist you in performing treatments in the Comfort of Your Office | Yes |
FDA Post Approval 5-Year Follow-up Study Completed & Accepted “Prevention of BPH Progression By Stabilizing PSA & Prostate Volume”
| Post-Treatment Catheter-Free Rate | 85% |
| Stabilization of BPH Symptoms | 83% reported No Progression at Year 5 |
| Erectile Dysfunction/Retrograde Ejaculation | 0.3 per 100 person-years |
| Significant Improvement of Mean AUA Symptom Score | Baseline = 20.1 vs. Year 5 = 12.8 |
| Significant Improvement of Peak Flow Rate (Qmax) | Baseline = 8.6 mL/s vs. Year 5 = 12.8 mL/s |
| Significant Improvement of Quality of Life (QOL) Score | Baseline = 22 vs. Year 5 = 16 |
© 2024 Medifocus Inc. | All rights reserved. | Important Information | Private Policy | Developed by Kohn Creative
